Bioservo Q3’22: Breakthrough at the horizon - Redeye

Redeye reduces our short-term lower estimated number of systems to be sold during 2022e and, to an extent, in 2023e. The estimate changes lower our Base Case to SEK 6 (8) per share, partly also due to a higher risk-free rate in our model. We still see a compelling long-term case; however, with the financing sorted, the pathway to commercialization is more straightforward.

Länk till analysen i sin helhet: https://www.redeye.se/research/863145/bioservo-q322-breakthrough-at-the-horizon?utm_source=finwire&utm_medium=RSS